Suchergebnisse - (Person:"De Meyer, Sandra")

PubPharm (11)

1

Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials

enthalten in: Journal of medical virology | 2021

von Lathouwers, E. | Weinsteiger, S. | Baugh, B. | +5

2

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

enthalten in: AIDS research and human retroviruses | 2020

von Lathouwers, E. | Wong, E. | Brown, K. | +108

3

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

enthalten in: Antiviral therapy | 2013

von Lathouwers, E. | De La Rosa, G. | Van de Casteele, T. | +4

4

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

enthalten in: Current HIV research | 2012

von Bánhegyi, D. | Katlama, C. | da Cunha, C. | +7

5

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

enthalten in: Antiviral therapy | 2010

von Dierynck, I. | De Meyer, S. | Lathouwers, E. | +5

6

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

enthalten in: AIDS (London, England) | 2009

von De Meyer, S. | Lathouwers, E. | Dierynck, I. | +7

7

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2008

von De Meyer, S. | Hill, A. | Picchio, G. | +3

CommentOn: AIDS. 2007 Oct 18;21(16):2245-8. - PMID 18090054

8

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2008

von De Meyer, S. | Spinosa-Guzman, S. | Vangeneugden, T. | +2

9

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

enthalten in: AIDS (London, England) | 2008

von Ortiz, R. | Dejesus, E. | Khanlou, H. | +9

10

Resistance profile of darunavir : combined 24-week results from the POWER trials

enthalten in: AIDS research and human retroviruses | 2008

von de Meyer, S. | Vangeneugden, T. | van Baelen, B. | +5